Immunophenotypic Aberrations, DNA Content, and Cell Cycle Analysis of Plasma Cells in Patients with Myeloma and Monoclonal Gammopathies
- 1 December 2000
- journal article
- research article
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 26 (6) , 634-645
- https://doi.org/10.1006/bcmd.2000.0342
Abstract
No abstract availableKeywords
This publication has 104 references indexed in Scilit:
- Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on eastern cooperative oncology group treatment trial E9486American Journal of Hematology, 1999
- A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1British Journal of Haematology, 1996
- DNA Cell Content Studies in Multiple MyelomaLeukemia & Lymphoma, 1996
- Role of Cytokines in the Pathogenesis of Monoclonal GammopathiesMayo Clinic Proceedings, 1994
- Multiple Myeloma: How Did It Begin?Mayo Clinic Proceedings, 1994
- Cell Surface Markers in Multiple MyelomaMayo Clinic Proceedings, 1994
- Markers of Multiple Hematopoietic-Cell Lineages in Multiple MyelomaNew England Journal of Medicine, 1990
- Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.Journal of Clinical Investigation, 1989
- Monoclonal gammopathy of undetermined significance and smoldering multiple myelomaEuropean Journal of Haematology, 1989
- Immunofluorescence Labeling Indices in Myeloma and Related Monoclonal GammopathiesMayo Clinic Proceedings, 1987